INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Modified PTO Form 1449

Atty. Docket No. 11245/46604	Serial No.07/840/146 Not Yet Assigned
Applicant Harlan W. WAKSAL	
Filing Date April 24 2001	Group 1647_

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
ALH	4,863,902	9/5/89	Amagase et al			
Aut	4,943,533	7/24/98	Mendelsohn et al.			
.Aut	5,846,565	12/8/98	Brem et al.			
Alt	5,468,754	11/21/95	Hausheer et al.			
Mit	5,559,235	9/24/96	Luzzio et al.			
MH	5,604,233	2/18/97	Hausheer et al.			
MH	5,880,133	3/9/99	Hausheer et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER	DOCUMENT					TRANSL	ATION
INITIAL	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
Art	EP 0 359 282 B1	5/95	EPO				

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.			
AUL	Han et al., "Preferential Inhibition of Glioblastoma Cells With Wild-Type Epidermal Growth Factor Receptors by a Novel Tyrosine Kinase Inhibitor Ethyl-2,5-Dihydroxycinnamate"; Oncology Research, Vol. 9, pages 581-587 (1997)			

COPY OF PAPERS ORIGINALLY FILED

			ATTY. DOCKET NO. 11245/46604	SERI 09/84	AL NO. 0,146
INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449		APPLICANT H. WAKSAL		MINER, int_Howerd	
		0-1447	FILING DATE April 24, 2001	GRO 1642	/ " "
		U. S.	PATENT DOCUMENTS		FEB 2 0 2002
EVAMINED	PATENT	PATENT		CLASS S	IBCLAS TRANSHES

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	DATE
				+		

FOREIGN PATENT DOCUMENTS

EXAMINER	DOCUMENT	2.00		ar	aupar	TRANSL	ATTON
INITIAL	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
				RE	CEIVE	\mathbb{C}^{2}	
					CH 9 6 20:	,	
			1.	ŀ	FB 7 0 500	<i>'</i> .	
				TECHO	ENTER 1600	1/2900	

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
MH	U.S. Patent Application of Dr. Mark Rubin, filed March 2001

EXAMINER (Une Melleran	DATE CONSIDERED 12/16/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYOI 45973601

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.				
MI		Baselga et al., "The epidermal growth factor receptor as a target for therapy in breast carcinoma", Breast Cancer Research and Treatment, Volume 29, pages 127-138 (1994)				
Ar#		Osband and Ross, "Problems in the investigational study and clinical use of cancer immunotherapy", Immunotherapy, pages 193-195				
AH		"Antitumor Effects of Doxorubicin in Combination with Anti-epidermal Growth Factor Receptor Monoclonal Antibodies", J. Baselga, L. Norton, H. Masui, A. Pandiella, K. Coplan, W.H. Miller, Jr., J. Mendelsohn; Journal of the National Cancer Institute, Vol. 35, No. 16, 1327-1333 (1993)				
Mit		"Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis- Diamminedichloroplatinum on Well Established A431 Cell Xenografts", Z. Fan, J. Baselga, H. Masui, J. Mendelsohn; Cancer Research, Vol. 53, 4637-4641(1993)				
Art		"Anti-tumor and Cell Cycle Responses on KB Cells Treatment with a Chimeric Anti-EGFR Monoclonal Antibody Incombination with Cisplatin", M. Prewett, P. Rockwell, C. Rose, N.I. Goldstein, Immunology Department, Inclone Systems, Inc., International Journal of Oncology 2以 224(1996)				
Prit		Abstract entitled "Immunochemotherapy of Human Transitional Cell Carcinoma (TCC) with Anti-EGF-R Monoclonal Antibody (Mab) C225 and the Anti-cancer Drugs, Taxol and Cisplatinum", AACR Annual Meeting, March 28-April 1998, New Orleans, LA 34, 79, 64 tun, 4, 3.				
Ar#	-16	"Inhibition of Human Tumor Growth in Nude Mice by a Conjugate of Doxorubicin with Monoclonal Antibodies to Epidermal Growth Factor Receptor", E. Aboud-Pirak, E. Hurwitz, F. Bellot, J. Schlessinger, M. Sela, Proc. Natl. Acad. Ser. U.S.A., Vol. 86, pp. 3778-3781 (1989)				
ArH		"Role of Protein Tyrosine Kinase Receptors in Cancer: Possibil Rockwell, N.I. Goldstein; Minecular and Cellular Dir. 3 (4) 315 MgCumlow hift errors	-335 (1995)			
Examiner	Qu	ne L'Allin	Date Considered			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{*}copy of reference is not enclosed because reference is cited in search report